Analysis on the Effect of Metformin Hydrochloride Combined with Insulin Pump for Gestational Diabetes Mellitus
Abstract
Background: U To analyze the effect of metformin hydrochloride combined with insulin pump for gestational diabetes mellitus (GDM).
Methods: Overall, 216 patients with GDM in Zhangqiu Maternity and Child Care Hospital, Jinan, China from Aug 2018 to Dec 2020 were enrolled and randomized into research and control groups. Patients in the control group were treated with insulin pump, while those in the research group were treated with metformin hydrochloride combined with insulin pump. The clinical efficacy, blood glucose levels, serum Betatrophin, C reactive protein (CRP), Cystatin C (Cys-C), homocysteine (Hcy), adiponectin, tumor necrosis factor (TNF-α), interleukin-6 (IL-6) content, incidence of adverse pregnancy outcomes and incidence of adverse newborns of patients in the two groups were compared.
Results: After treatment, the total clinical efficiency of the research group was 84.26%, significantly higher than that of the control group (68.52%). The levels of FPG, 2hPG, HbAlc, serum Betatrophin, CRP, CysC, Hcy, adiponectin factors, TNF-α, and IL-6 in the research group were lower than those in the control group, with statistically significant differences (P<0.05). The overall incidence of adverse pregnancy outcomes was 10.19% in the research group, and 25.93% in the control group. The comparative differences between the two groups were statistically significant (P<0.05). The overall incidence of adverse newborns was 9.26% in the research group, and 21.30% in the control group. The comparative differences between the two groups were statistically significant as well (P<0.05).
Conclusion: Metformin hydrochloride combined with insulin pump for GDM can significantly reduce blood glucose level, regulate serum protein factor levels, and improve adverse outcomes for mother and child, which deserves clinical promotion.
2. Radzicka S, Pietryga M, Iciek R, Brązert J (2018). The role of visfatin in pathogene-sis of gestational diabetes (GDM). Ginekol Pol, 89(9): 518-521.
3. Khambule L, George JA (2019). The Role of Inflammation in the Development of GDM and the Use of Markers of In-flammation in GDM Screening. Adv Exp Med Biol, 1134: 217-242.
4. Vince K, Perković P, Matijević R (2020). What is known and what remains unre-solved regarding gestational diabetes mellitus (GDM). J Perinat Med, 48(8): 757-763.
5. Dhingra A, Ahuja K (2016). Lifestyle modi-fications for GDM. J Pak Med Assoc, 66(9 Suppl1): S34-S38.
6. Caissutti C, Berghella V (2017). Scientific Ev-idence for Different Options for GDM Screening and Management: Controver-sies and Review of the Literature. Biomed Res Int, 2017: 2746471.
7. Boriboonhirunsarn D, Sunsaneevithayakul P, Pannin C, Wamuk T (2021). Prevalence of early-onset GDM and associated risk factors in a university hospital in Thai-land. J Obstet Gynaecol, 41(6):915-919.
8. Garsany Y, Bancroft CH, Atkinson Iii RW, et al (2020). Effect of GDM Pairing on PEMFC Performance in Flow-Through and Dead-Ended Anode Mode. Molecules, 25(6): 1469.
9. Lacroix M, Lizotte F, Hivert MF, Geraldes P, Perron P (2019). Calcifediol Decreases Interleukin-6 Secretion by Cultured Hu-man Trophoblasts From GDM Preg-nancies. J Endocr Soc, 3(11): 2165-2178.
10. Sharma AK, Taneja G, Kumar A,et al (2019). Insulin analogs: Glimpse on contempo-rary facts and future prospective. Life Sci, 219: 90-99.
11. McCreight LJ, Bailey CJ, Pearson ER (2016). Metformin and the gastrointestinal tract. Diabetologia, 59(3): 426-35.
12. Fujita Y, Inagaki N (2017). Metformin: New Preparations and Nonglycemic Benefits. Curr Diab Rep, 17(1): 5.
13. Dude A, Niznik CM, Szmuilowicz ED, Peaceman AM, Yee LM (2018). Man-agement of Diabetes in the Intrapartum and Postpartum Patient. Am J Perinatol, 35(11): 1119-1126.
14. Kautzky-Willer A, Harreiter J, Winhofer-Stöckl Y, et al (2019). [Gestational diabe-tes mellitus (Update 2019)]. Wien Klin Wochenschr, 131(Suppl 1): 91-102.
15. Bashir M, Aboulfotouh M, Dabbous Z, et al (2020). Metformin-treated-GDM has lower risk of macrosomia compared to diet-treated GDM- a retrospective cohort study. J Matern Fetal Neonatal Med, 33(14): 2366-2371.
16. Plant N, Šumilo D, Chapman R, Webber J, Saravanan P, Nirantharakumar K (2020). Unmet needs of women with GDM: a health needs assessment in Sandwell, West Midlands. J Public Health (Oxf), 42(4): e516-e524.
17. Fakhrul-Alam M, Sharmin-Jahan, Mashfiqul-Hasan,et al (2020). Insulin secretory de-fect may be the major determinant of GDM in lean mothers. J Clin Transl Endo-crinol, 20: 100226.
18. Huvinen E, Eriksson JG, Stach-Lempinen B, Tiitinen A, Koivusalo SB (2018). Het-erogeneity of gestational diabetes (GDM) and challenges in developing a GDM risk score. Acta Diabetol, 55(12): 1251-1259.
19. Steinhilber B, Haupt G, Miller R, Janssen P, Krauss I (2017). Exercise therapy in pa-tients with hip osteoarthritis: Effect on hip muscle strength and safety aspects of exercise-results of a randomized con-trolled trial. Mod Rheumatol, 27(3): 493-502.
20. Owen L, Corfe B (2017). The role of diet and nutrition on mental health and well-being. Proc Nutr Soc, 76(4): 425-426.
21. Shi S, Kong N, Feng C, et al (2019). Drug Delivery Strategies for the Treatment of Metabolic Diseases. Adv Healthc Mater, 8(12): e1801655.
22. Mathieu C, Gillard P, Benhalima K (2017). Insulin analogues in type 1 diabetes melli-tus: getting better all the time. Nat Rev En-docrinol, 13(7): 385-399.
23. Rodbard HW, Rodbard D (2020). Biosyn-thetic Human Insulin and Insulin Ana-logs. Am J Ther, 27(1): e42-e51.
24. Heise T, Meneghini LF (2014). Insulin stack-ing versus therapeutic accumulation: un-derstanding the differences. Endocr Pract, 20(1): 75-83.
25. Lv Z, Guo Y (2020). Metformin and Its Benefits for Various Diseases. Front Endo-crinol (Lausanne), 11: 191.
26. DeFronzo R, Fleming GA, Chen K, Bicsak TA (2016). Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism, 65(2): 20-29.
27. Podhorecka M, Ibanez B, Dmoszyńska A (2017). Metformin - its potential anti-cancer and anti-aging effects. Postepy Hig Med Dosw (Online), 71(10): 170-175.
28. Papamichael K, Chachu KA, Vajravelu RK,et al (2017). Improved Long-term Out-comes of Patients With Inflammatory Bowel Disease Receiving Proactive Com-pared With Reactive Monitoring of Se-rum Concentrations of Infliximab. Clin Gastroenterol Hepatol, 15(10): 1580-1588.e3.
29. Minamoto Y, Otoni CC, Steelman SM, et al (2015). Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel dis-ease. Gut Microbes, 6(1): 33-47.
30. Stenwall PA, Bergström M, Seiron P, et al (2015). Improving the anti-inflammatory effect of serum eye drops using allogene-ic serum permissive for regulatory T cell induction. Acta Ophthalmol, 93(7): 654-657.
31. Wang IK, Wu YY, Yang YF, et al (2015). The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benef Mi-crobes, 6(4): 423-430.
32. Irmscher S, Brix SR, Zipfel SLH, et al (2019). Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopa-thies. Nat Commun, 10: 2961.
| Files | ||
| Issue | Vol 51 No 1 (2022) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v51i1.8298 | |
| Keywords | ||
| Metformin hydrochloride Insulin pump Gestational diabetes mellitus Clinical efficacy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
